Innovate Corp (NYSE: VATE) is a diversified holding company that operates a portfolio of businesses across infrastructure, spectrum broadcasting, and life sciences. Revenue is generated through project-based construction and fabrication work at its infrastructure subsidiary DBMG (headquartered in Phoenix, Arizona), broadcast advertising and licensing across a large network of LPTV and full-power television stations in its Spectrum segment (headquartered in New York, New York), and early-stage commercialization activity at its Life Sciences segment through Pansend Life Sciences. As of the 10-K filed 2026-03-26, management has initiated a formal sales process for both the Infrastructure and Spectrum segments, required by milestone covenants added to debt agreements during the third quarter of 2025 refinancing. Following those divestitures, the company's stated strategic focus shifts to managing and building value in its remaining segments. Corporate headquarters are located in New York, New York.

Revenue model

Revenue is generated across three active segments: project-based steel fabrication and erection contracts at DBMG (Infrastructure), broadcast advertising and station licensing fees across a network of LPTV and full-power television stations (Spectrum), and early-stage product commercialization and investment returns at Pansend Life Sciences (Life Sciences). The company operates as a holding company, with segment-level operating businesses generating their own cash flows.

Products and services

Infrastructure: structural steel fabrication and erection services through DBMG, which uses both in-house capacity and third-party fabrication, erection, and detailing subcontractors. Spectrum: LPTV stations, Class A stations, and full-power television stations across more than 100 designated market areas in the United States, including Puerto Rico. Life Sciences: Genovel Orthopedics (80.0% controlling interest as of December 31, 2025) developing products to treat early osteoarthritis of the knee; R2 Technologies (81.0% controlling interest as of December 31, 2025) developing and commercializing the Glacial platform for precision contact cooling of the skin in the aesthetic dermatology market; minority stakes in MediBeacon (44.6%), Triple Ring Technologies (1.6% fully diluted), and Scaled Cell Solutions (20.1%), all as of December 31, 2025.

Customers and end markets

Infrastructure end markets include commercial and industrial construction requiring structural steel fabrication and erection. Spectrum end markets include local television advertising buyers across U.S. designated market areas, reaching audiences in markets ranked from major metros down to smaller regional markets across more than 40 states and Puerto Rico. Life Sciences end markets include the aesthetic dermatology and orthopedic medical device markets, with R2 Technologies targeting the skin lightening and brightening segment of aesthetic dermatology.

Value-chain role

Holding company and capital allocator across operating subsidiaries. At the segment level: DBMG is a project contractor and fabricator in structural steel construction; Spectrum is a broadcast station operator and content distributor; Pansend is an early-stage life sciences investor and controlling shareholder in development-stage medical device companies.

Geographic exposure

Corporate headquarters in New York, New York. DBMG headquartered in Phoenix, Arizona. Spectrum segment headquartered in New York, New York, with television stations spread across more than 100 U.S. designated market areas including Puerto Rico. R2 Technologies headquartered in Dublin, California. The company notes it owns fabrication facilities, warehouses, and office space in various countries where it operates, per the 10-K filed 2026-03-26.

Source: SEC 10-K, filed 2026-03-26

Industry: Fabricated Structural Metal Products Peers: Limbach Holdings Inc Bowman Consulting Group Ltd. Orbital Infrastructure Group, Inc. NOS4-1, Inc. Matrix Service Co Orion Group Holdings Inc QualTek Services Inc. Quanta Services Inc